Tandem CD20-CD19-Directed CAR T-Cell Therapy for Relapsed/Refractory DLBCL: Zamtocabtagene Autoleucel
The first pivotal trial of a tandem CD20-CD19 directed non-cryopreserved CAR T-cell product for patients with third-line relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) demonstrated encouraging activity and a favorable safety profile, according to a pre-planned interim analysis presented by Nirav Shah, MD, Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
This pre-planned interim analysis reports on efficacy and safety outcomes from the phase 2 DALY II USA clinical trial of zamtocabtagene autoleucel (zamto-cel), an investigational autologous tandem CD20-CD19-directed non-cryopreserved CAR-T cell product.
Dr Shah presented these results at the 66th ASH Annual Meeting in San Diego, California.
“Among the 59 evaluable patients at the interim analysis, there is encouraging activity and a favorable safety profile in DLBCL patients treated with zamto-cel,” wrote Dr Shah and colleagues. “Unlike currently registered CAR-T cell products, zamto-cel is administered as a fresh product with a short vein-to-vein time of 14 days with lymphodepletion initiated during the manufacturing process.”
“With a manufacturing success rate of 91% we have demonstrated the feasibility of this process among high-risk patients with R/R DLBCL,” they added.
Source:
Shah N, Maziarz R, Jacobson C, et al. Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Presented at the 66th ASH Annual Meeting & Exposition; December 7-10, 2024; San Diego, California. Abstract 68.
